Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

Alzheimer Disease Clinical Trial

Official title: Light, Metabolic Syndrome and Alzheimer's Disease: A Non-Pharmocological Approach

Status Recruiting

Clinical Trial Summary

To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).

Clinical Trial Description

Test if a tailored light intervention (TLI) that promotes entrainment can improve sleep disturbances, inflammation, insulin sensitivity (Si) and glucose disposal (Sg) and cognition in patients with MCI and mild ADRD and sleep disturbances. Using a single-arm, between-subjects, placebo-controlled study the investigators will investigate if long-term (6-month) exposure to TLI improves glucose homeostasis and insulin sensitivity in patients with MCI and mild AD who suffer from sleep disturbance and are living at home. Participants will be recruited from the Mount Sinai AD research center (ADRC) and randomized to receive the TLI (or comparison control treatment) at home. The investigators hypothesize that, compared to the comparison light, a TLI will increase entrainment, improve sleep, reduce depression, reduce inflammation, improve metabolic control, increase insulin sensitivity, and reduce susceptibility to T2DM and metabolic disease during and after the completion of the 6-month intervention. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Metabolic Syndrome
• Mild Cognitive Impairment
• Type2 Diabetes

• NCT number: NCT03933696
• Study type: Interventional
• Source: Icahn School of Medicine at Mount Sinai
• Contact: Christoph Buettner, MD, PhD
• Phone: 212-241-3425
• Email: cb1116@rwjms.rutgers.edu
• Status: Recruiting
• Phase: N/A
• Start date: January 2, 2019
• Completion date: May 31, 2024